Tom Schoenherr

Immunexpress has appointed Rolland Carlson, Tanja Dowe, and Katleen Verleysen to its board. The company also noted that Bea Arnold has stepped down from the board after a three-year tenure.

Carlson was appointed CEO of Immunexpress last month, and previously served as president and CEO at both WaferGen Biosystems and Asuragen. Dowe currently serves as CEO of Debiopharm Innovation Fund, the strategic corporate fund of Debiopharm Group. Verleysen is CEO of CellSeeQ. Prior to that, she held various positions at Pronota, including CEO and chief operating officer.

Angle announced today that it has appointed Greg Shaw to its scientific advisory board. Shaw is currently a consultant urological surgeon at the University College Hospital in London. He is also chief investigator for two studies at the National Institute for Health Research investigating the effects of refinements to robotic surgery and the use of drugs to prevent progression in men on active surveillance for prostate cancer. 

Michael Stocum has stepped down as CEO of Inivata "to pursue other interests," according to the company. Inivata said it has initiated a search for a new CEO.

Centogene announced today that it has appointed Berndt Modig to its supervisory board. Modig currently serves as director and audit committe chair of Axovant Sciences, member of the audit committee of Affimend, and vice chairman of the supervisory board and chair of the audit committee at Kiadis Pharma. In addition, Modig is currently CEO and co-founder of Pharvaris.

Modig previously served as CFO of Prosensa Hodling from Mar. 2010 until its 2015 acquisiotn by BioMarin Pharmaceutical. Prior to Prosensa holding, Modig was CFO at Jerini AG. Modig has also held a variety of senior management positions at Surplex AG, Hayward Industrial Products, Agra Industrial, and Price Waterhouse. 

Becton Dickinson has announced three executive leadership changes. Alberto Mas will now lead the firm's medical segment; Patrick Kaltenbach will head up life sciences, replacing Mas, effective May 29; and Bill Tozzi will lead the firm's interventional segment on an interim basis.

Mas was head of BD's life sciences business for two years, and previously served as president of three of the firm's other major business units. Kaltenbach previously served as senior vice president of life sciences and applied markets at Agilent. Tozzi had been serving as the integration leader for the CR Bard transaction since April 2017, and prior to that was the president of the firm's medication delivery solutions division for six years. Tozzi will replace John Groetelaars, who served as the president of the interventional segment since the completion of the Bard transaction and who has decided to leave BD for an executive position at another company.

Mas was head of Life Sciences for two years, and previously served as president of three of the firms other major business units. 

Kaltenbach will replace Mas effective May 29, 2018. He previously served as senior vice president of life sciences and applied markets at Agilent, a position he held since 2014.

Tozzi had been serving as the integration leader for the CR Bard transaction since April 2017, and prior to that was the president of the firm's medication delivery solutions division for six years. Tozzi will replace John Groetelaars, who served as the president of the interventional segment since the completion of the Bard transaction and who has decided to leave BD for an executive position at another company.

Exact Sciences Chief Operating Officer Maneesh Arora will be leaving the company at the end of the year. During a conference call with analysts following the release of the company's first quarter earnings, Exact CEO Kevin Conroy announced that Arora "will transition to a life outside of Exact Sciences," adding that he will spend the rest of 2018 "focusing his operational and strategic rigor on the priority of advancing our pipeline plans to fuel our future success." The company does not anticipate finding a replacement COO at this time, Conroy noted.